Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Bristol Myers Squibb Company (NYSE:BMY) have earned an average rating of “Hold” from the twenty-one brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $54.6154.

A number of equities research analysts have recently issued reports on BMY shares. Scotiabank reiterated a “sector perform” rating and set a $53.00 price target (up from $45.00) on shares of Bristol Myers Squibb in a research report on Thursday, December 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd.

Bristol Myers Squibb Trading Up 0.2%

NYSE:BMY opened at $54.22 on Wednesday. The stock has a market capitalization of $110.38 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 8.28 and a beta of 0.29. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33. The stock has a fifty day moving average price of $49.23 and a two-hundred day moving average price of $47.39. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the prior year, the company posted $1.80 EPS. The business’s revenue for the quarter was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 83.78%.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of large investors have recently bought and sold shares of BMY. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. CBIZ Investment Advisory Services LLC lifted its holdings in Bristol Myers Squibb by 66.0% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 231 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Bristol Myers Squibb during the 1st quarter worth about $36,000. Finally, Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.